Regorafenib Induces Rapid and Reversible Changes in Plasma Nitric Oxide and Endothelin-1 | Zendy

Nilka de Jesús-González | Zendy; Emily Robinson | Zendy; Radostin Penchev | Zendy; Margaret von Mehren | Zendy; Michael C. Heinrich | Zendy; William D. Tap | Zendy; Qian Wang | Zendy; George D. Demetri | Zendy; Suzanne George | Zendy; Benjamin D. Humphreys | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Regorafenib Induces Rapid and Reversible Changes in Plasma Nitric Oxide and Endothelin-1

Author(s) -

Nilka de Jesús-González,

Emily Robinson,

Radostin Penchev,

Margaret von Mehren,

Michael C. Heinrich,

William D. Tap,

Qian Wang,

George D. Demetri,

Suzanne George,

Benjamin D. Humphreys

Publication year - 2012

Publication title -

american journal of hypertension

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.009

H-Index - 136

eISSN - 1941-7225

pISSN - 0895-7061

DOI - 10.1038/ajh.2012.97

Subject(s) - medicine , regorafenib , bosentan , endothelin receptor , nitric oxide , stimulation , pharmacology , endothelin 1 , oncology , colorectal cancer , receptor , cancer

Hypertension is a toxicity of antiangiogenic therapies and a possible biomarker that identifies patients with superior cancer outcomes. Understanding its mechanism will aid in treatment and could lead to the development of other biomarkers for predicting toxicity and anticancer efficacy. Recent evidence implicates nitric oxide (NO) suppression and endothelin-1 (ET-1) stimulation as potential mechanisms leading to antiangiogenic therapy-induced hypertension. The aim of this study was to evaluate the effects of regorafenib, a novel broad-spectrum kinase inhibitor with activity against multiple targets, including vascular endothelial growth factor receptor 2 inhibition, on NO and ET-1 levels.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research